Amarin Corp Plc (AMRN)

[Whalatane]

JL , Gabor , GG et al

We were discussing JELIS Secondary Analysis

https://www.researchgate.net/profile/Yuji_Matsuzawa/publication/24409933_Incremental_Effects_of_Eicosapentaenoic_Acid_on_Cardiovascular_Events_in_Statin-Treated_Patients_With_Coronary_Artery_Disease_-_Secondary_Prevention_Analysis_From_JEL

JL , I am not saying CABG and prior MI's are 53% of the 3664 souls in JELIS 2ndry
There is obvious over lap ...chk the math .

JELIS secondary total 3,664 patients

They report PTCA or CABG totaled 895 patients
Prior MI totaled 1,050 patients
Stable AP totaled 2,903 patients
----------------
TOTAL = 4,848 patients

So obvious over lap .
There were 484 patients with both stable AP and coronary intervention and 537 patients with prior MI and coronary intervention.

What appears to me as likely over reporting of Stable AP , skews the CVD event rate lower then what it may be in a more vigorously controlled trial.
Therefore I don't agree with your statement that " the CVD risk in R-IT (placebo ) group is two and one half the times in JELIS"

I agree that the CVD event rate in R-IT will be higher because of a higher % of diabetics in R-IT ( over 60% in R-IT vs 23% in JELIS 2ndry ) and a certain % with CKD in R-IT ( none reported in JELIS ) ....just not as high as you expect it to be ....

I don't think the 2.3 % CVD rate you use in JELIS is a reliable figure
JMO
Kiwi